N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
In this study, we retrospectively will investigate safety and efficacy of NAC dose given in paracetamol toxicity as an adjuvant therapy in critically ill COVID-19 patients with acute respiratory distress and determine whether NAC in high doses can avoid respiratory failure in patients with COVID-19.
Epistemonikos ID: 604064fe58f3fb317a04d22f5f1b0a756671f628
First added on: Aug 18, 2022